Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Akebia, Vifor in distribution deal for vadadustat

Akebia Therapeutics Inc. (NASDAQ:AKBA) was up $1.87 (14%) to $14.77 in after-hours trading after it said it granted Vifor Pharma Group (SIX:VIFN) exclusive U.S. distribution rights to vadadustat (formerly AKB-6548)

Read the full 309 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE